Previous 10 | Next 10 |
AZEDRA ® (iobenguane I 131) U.S. Commercial Launch Advancing with 22 Treatment Requests from Patients Received and 12 Centers Throughout the U.S. are Ready to Treat Patients Phase 2 Trial of 1095 Initiated with Enrollment to Begin 2Q 2019 Phase 3 CONDOR Trial of PyL TM Enrolling ...
ALPHARETTA, Ga. , May 8, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with its affiliates, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics", "you" or the "Company")(NASDAQ: PGNX), today publicly called on the Company's manag...
The following slide deck was published by Progenics Pharmaceuticals, Inc. in conjunction with this Read more ...
NEW YORK, May 07, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX, “Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today issued the fol...
It takes 20 years to build a reputation and five minutes to ruin it. If you think about that, you'll do things differently. - Warren Buffett Progenics Pharmaceuticals ( PGNX ) is a prime example of the need for investors to keep up with investments. I'm correct in my forecast of the Aze...
Progenics Board Deeply Committed to Enhancing Value for all Shareholders Repeated Efforts to Engage Meaningfully with Velan Rebuffed No Shareholder Action Required at this Time NEW YORK, May 06, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) ( ...
-Phase 2/3 OSPREY Data Demonstrates PyL’s High Specificity and Sensitivity in Detecting Prostate Cancer- -Data Generated Under PyL Research Access Program Supports Potential of PyL to Detect Disease in Biochemical Recurrent Patients, Including Those with Low PSA Scores, and Impa...
ALPHARETTA, Ga. , May 6, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with its affiliates, "Velan"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (the "Company")(NASDAQ: PGNX), today announced that it has delivered a letter to the Board of Directors (the "Board...
NEW YORK, May 02, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review firs...
NEW YORK, April 24, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an analysis of an ongoing investigator-initiated st...
News, Short Squeeze, Breakout and More Instantly...
Progenics Pharmaceuticals Inc. Company Name:
PGNX Stock Symbol:
NASDAQ Market:
Progenics Pharmaceuticals Inc. Website:
The second half of the year could provide some solid wins for investors in the cancer therapeutics market. In recent years, Wall Street has flocked to many of these biotechnology companies because of their potential to deliver cutting-edge treatments and generate long-term returns. As cancer ...
Biopharma Dynavax Technologies (NASDAQ: DVAX) is one of many companies racing to develop a COVID-19 vaccine. Like many coronavirus-focused companies, Dynavax has seen its shares rise on the ongoing concern related to the pandemic -- in its case, by 50% year to date. While investors may co...
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it...